Background: Hypertension clinic, Srinagarind hospital has established since April 2003. Our aims are to teach medical students in taking care of hypertensive patients and give a comprehensive and holistic care for hypertensive. We would like to evaluate patients characteristics and outcome of treatment in our clinic that will be baseline data to and improve our service.
Objective: To assess clinical outcome of hypertensive treated at hypertension clinic, Srinagarind hospital.
Population: Patients diagnosed as hypertension and treated at hypertension clinic, Srinagarind hospital for at least one year.
Sampling: 100 cases by simple random sampling from 200 populations
Tool: Record form and out-patient department record
Analysis: Descriptive statistics and analytical statistics
Results: There were 100 persons enrolled, 62 female. The mean ages were 59 +17.7 and 57.4 + 10.6 years old in female and male, respectively. The average duration after diagnosis as hypertension was 4.5 years. The mean BMI and mean abdominal circumference in male were 27.2 + 0.6 kg/m2 and 94.8 + 0.8 centimeters, respectively. In female group, both variables were 26.3 + 0.9 kg/m2 and 92.9 + 5.6 centimeters, respectively.The three most common anti-hypertensive drug uses were ACEI (38%), hydrochlorothiazide (35%), and beta blocker (35%). Side effects were found in 18 patients; ACEI induced cough (10%) was the most common one. Good control of hypertension was achieved in 92 patients with one or two medications. Left ventricular hypertrophy was the most common complication in our studied cases, 20 cases. According to International Diabetes Federation (IDF, 2005) criteria, there were 54 cases met metabolic syndrome criteria. Diabetes mellitus or impaired fasting glucose (IFG) was found in 45 cases.
Conclusion: The control rate of hypertensive patients treated at hypertension clinic, Srinagarind hospital was 92% with one or two antihypertensive drugs. Half of cases were associated with metabolic syndrome and/or diabetes mellitus or IFG.
1.Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
2.Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-15.
3.Jago R, Harrell JS, McMurray RG, Edelstein S, El Ghormli L, Bassin S. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics 2006 ;117:2065-73.
4.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
5.Vasan RS, Larson MG, Leip EP, Evans JC, ODonnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
8.Fisher NDL, Williams GH. Hypertensive vascular disease. In: Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrisons principles of internal medicine. New York: McGraw-Hill, 16th edition, 2005:1463-81.
9.WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Health Communications Australia Pty Ltd, 2000.
10.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
11.Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82.
12.Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
13.American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes care 2003;26:S80-2.
14.No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
15.Singh NP, Uppal M, Anuradha S, Agarwal A, Rizvi SN. Angiotensin converting enzyme inhibitors and cough--a north Indian study. J Assoc Physicians India 1998;46:448-51.
16.Sawanyawisuth K, Limpawattana P, Mahakkanukrauh A, Wongvipaporn C. The Rate of Checking Urine Microalbumin and Aspirin Primary Prevention in Type 2 DM. J Med Assoc Thai 2006;89:636-31.